# A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT05487235** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 57 (actual)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** GDC-1971
- **DRUG:** Atezolizumab
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT05487235
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-17
- **Primary completion:** 2025-06-23
- **Final completion:** 2025-06-23
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487235, "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05487235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*